# Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

> **NCT01841697** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 642 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Omarigliptin
- **DRUG:** Sitagliptin
- **DRUG:** Placebo to omarigliptin
- **DRUG:** Placebo to Sitagliptin
- **DRUG:** Open-label Metformin
- **DRUG:** Open-label Glimepiride

## Key facts

- **NCT ID:** NCT01841697
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-13
- **Primary completion:** 2014-11-17
- **Final completion:** 2014-11-17
- **Target enrollment:** 642 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01841697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01841697, "Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01841697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*